Live Breaking News & Updates on Biodrg|Page 4

Stay updated with breaking news from Biodrg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Immunitybio slumps as FDA declines to approve bladder cancer treatment

ImmunityBio Inc said on Thursday the U.S. Food and Drug Administration has declined to approve its combination therapy to treat a type of bladder cancer due to deficiencies in the company's application. ....

Sriparna Roy , Immunitybio Inc , Drug Administration , Thomson Reuters Trust Principles , Bacillus Calmette Gu , Thomson Reuters Trust , Rsbi Regulatory Oversight , Rhpi Approvals , Rhpi Regulatory , Rhpi Public Health ,

BioNTech, Roche's experimental pancreatic cancer treatment wins Nature plaudit

Scientific journal Nature on Wednesday said a personalised treatment based on messenger RNA by BioNTech potentially bodes well for the future of fighting an extremely aggressive form of cancer after the regimen was shown to trigger a promising immune reaction in some pancreatic cancer patients. ....

New York , United States , Memorial Sloan Kettering Cancer Center , Ludwig Burger , Roche Rogs Genentech , Thomson Reuters Trust Principles , Thomson Reuters Trust , Ef Business Future Of Health ,

FDA reviewers flag concerns over Sarepta's gene therapy for muscle-wasting disorder

The U.S. Food and Drug Administration's staff reviewers raised concerns over limited data on Sarepta Therapeutics Inc's gene therapy for a muscle-wasting disorder, ahead of a meeting of the agency's advisers on Friday. ....

Sriraj Kalluvila , Leroy Leo , Thomson Reuters Trust Principles , Sarepta Therapeutics Inc , Drug Administration , Thomson Reuters Trust , Rsbi Regulatory Oversight , Rhpi Approvals , Rhpi Biopharma , Rhpi Drug Device Trials , Rhpi Regulatory , Ef Business Future Of Health ,

Pfizer beats profit estimates on demand for new drugs, COVID products

Pfizer Inc on Tuesday beat estimates for first-quarter revenue and profit, helped by steady demand for its COVID products and reaffirmed its annual earnings forecast as it banks on newer drugs to contribute to growth later this year. ....

Bhanvi Satija , Sriraj Kalluvila , Raghav Mahobe , Pfizer Inc , Thomson Reuters Trust Principles , Thomson Reuters Trust , Rhpi Commercial Strategy , Rhpi Government Health Policy , Rhpi Public Health ,

Pfizer, BioNTech propose EU pays half for each cancelled COVID dose, Financial Times reports

Pfizer Inc and BioNTech's new proposal to the European Union, amid a glut of COVID-19 shots, includes a provision for member states to pay half price, or about 10 euros ($11), for each of about 70 million cancelled doses, the Financial Times reported on Sunday. ....

Bruxelles Capitale , Urvi Dugar , European Medicines Agency , Thomson Reuters Trust Principles , European Union , Pfizer Inc , Financial Times , Thomson Reuters Trust , Rhpi Public Health ,